Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$43.66

0.03 (0.07%)

07:19
08/07/18
08/07
07:19
08/07/18
07:19

Ionis Pharmaceuticals expects to end FY18 with $1.8B in cash

The company said, "Our strong financial results were driven by a more than three-fold increase in commercial revenue from SPINRAZA compared to last year. Looking ahead to the second half of this year, we expect to continue to strengthen our financial performance as we add product sales from TEGSEDI and potentially WAYLIVRA to our growing SPINRAZA royalties. We also have the potential to earn numerous milestone payments from our partnered programs. In addition, we will have two full quarters of amortization from our expanded Biogen collaboration, providing further revenue growth," said Elizabeth L. Hougen, chief financial officer of Ionis. "We are on track to achieve our third consecutive year of pro forma operating income even as we prepare to launch two new drugs this year. In addition, we expect to end 2018 with more than $1.8B in cash."

  • 30

    Aug

  • 06

    Oct

IONS Ionis Pharmaceuticals
$43.66

0.03 (0.07%)

06/20/18
LEHM
06/20/18
DOWNGRADE
Target $45
LEHM
Underweight
Ionis Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Gena Wang downgraded Ionis Pharmaceuticals (IONS) to Underweight and lowered her price target for the shares to $45 from $52 after PTC Therapeutics (PTCT) reported competing spinal muscular atrophy data. Wang this morning also upgraded PTC to Equal Weight from Underweight.
06/20/18
LEHM
06/20/18
NO CHANGE
LEHM
Barclays upgrades PTC to Equal Weight, downgrades Ionis to Underweight
Barclays analyst Gena Wang upgraded PTC Therapeutics (PTCT) to Equal Weight from Underweight while downgrading Ionis Pharmaceuticals (IONS) to Underweight from Equal Weight. The analyst raised her price target on the former to $40 from $26 and lowered her price target on the latter to $45 from $52. Following PTC's new data in spinal muscular atrophy data, the analyst believes its risdiplam has "disruptive potential" to Ionis and Biogen's (BIIB) Spinraza.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis approval narrower than expected, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says the European approval of Tegsedi announced this morning Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) for the treatment of stage 1 or stage 2 polyneuropoathy in adult patients with hATTR was narrower than he originally expected. The indication is narrower than the broader hATTR patient population, inclusive of both cardiomyopathy and polyneuropathy, but makes sense considering that the pivotal trial primarily enrolled patients with stage 1 and 2 polyneuropathy, Van Buren tells investors in a research note. The analyst adds that while the approval is a positive development and Tegsedi represents the largest near-term pipeline opportunity for Ionis, he wants to observe positive early launch metrics and confirmation of the opportunity before getting more constructive on the shares. He keeps a Neutral rating on Ionis with a $50 price target.
07/23/18
OPCO
07/23/18
NO CHANGE
Target $400
OPCO
Outperform
Oppenheimer anticipating potential volatility ahead for Biogen
Oppenheimer analyst Jay Olson anticipates Biogen (BIIB) volatility driven by Q2 results along with AD presentations at AAIC that include promising BAN2401 data, which was recently top-lined. The analyst expects a focus on ADCOMS component scores and effect sizes for BAN2401. With regards to Q2 results, Olson expects top-line growth of 4% and non-GAAP EPS of $3.95 which is impacted by the Ionis Pharmaceuticals (IONS) deal upfront payment. Additionally, he expects continued strong Spinraza and biosimilar growth. Olson reiterates an Outperform rating and $400 price target on Biogen's shares.

TODAY'S FREE FLY STORIES

HSBC

HSBC

$41.91

0.15 (0.36%)

11:55
11/15/18
11/15
11:55
11/15/18
11:55
Options
HSBC put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
11/15/18
11/15
11:55
11/15/18
11:55
Conference/Events
RBC Capital telecom/data centers analyst to hold a group luncheon »

Telecom & Data…

QLYS

Qualys

$72.81

0.89 (1.24%)

11:55
11/15/18
11/15
11:55
11/15/18
11:55
Conference/Events
Qualys to hold analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 09

    Jan

11:55
11/15/18
11/15
11:55
11/15/18
11:55
Conference/Events
RBC Capital U.S. Internet analyst to hold a group luncheon »

U.S. Internet Analyst…

PRSP

Perspecta

$21.53

-0.8 (-3.58%)

11:54
11/15/18
11/15
11:54
11/15/18
11:54
Hot Stocks
Perspecta in partnership with Abaco Systems for 1553 Bus Defender product »

Perspecta announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$128.87

2.18 (1.72%)

11:49
11/15/18
11/15
11:49
11/15/18
11:49
Hot Stocks
Chubb board authorizes $1.5B share repurchase program »

Chubb's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COG

Cabot Oil & Gas

$25.55

-0.28 (-1.08%)

11:45
11/15/18
11/15
11:45
11/15/18
11:45
Options
Cabot Oil & Gas call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

11:45
11/15/18
11/15
11:45
11/15/18
11:45
General news
U.S. blue chips remain under pressure »

U.S. blue chips remain…

PM

Philip Morris

$84.99

-0.52 (-0.61%)

, BTI

British American Tobacco

$35.46

-1.05 (-2.88%)

11:41
11/15/18
11/15
11:41
11/15/18
11:41
Hot Stocks
FDA proposes steps to prevent flavored tobacco access, ban menthol cigarettes »

FDA Commissioner Scott…

PM

Philip Morris

$84.99

-0.52 (-0.61%)

BTI

British American Tobacco

$35.46

-1.05 (-2.88%)

MO

Altria Group

$58.38

-0.71 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$8.25

0.36 (4.56%)

11:35
11/15/18
11/15
11:35
11/15/18
11:35
Options
McDermott put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFT

Luxoft

$35.44

-3.3 (-8.52%)

11:33
11/15/18
11/15
11:33
11/15/18
11:33
Downgrade
Luxoft rating change  »

Luxoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TDY

Teledyne

$221.27

1.165 (0.53%)

11:31
11/15/18
11/15
11:31
11/15/18
11:31
Hot Stocks
Teledyne awarded $7.51M Navy contract »

Teledyne Microwave…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:30
11/15/18
11/15
11:30
11/15/18
11:30
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss the U.S.…

MDU

MDU Resources

$25.86

-0.265 (-1.01%)

11:30
11/15/18
11/15
11:30
11/15/18
11:30
Hot Stocks
MDU Resources increases quarterly dividend »

The MDU Resources Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$199.90

-2.53 (-1.25%)

11:29
11/15/18
11/15
11:29
11/15/18
11:29
Periodicals
Goldman Sachs CEO 'outraged' by 1MDB scandal, Bloomberg reports »

Goldman Sachs CEO David…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$78.25

-0.65 (-0.82%)

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Options
XPO Logistics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$32.50

-1.2 (-3.56%)

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Conference/Events
Biohaven Pharmaceutical management to meet with Morgan Stanley »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

EVFM

Evofem

$3.44

(0.00%)

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Conference/Events
Evofem to hold a key opinion leader event »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 27

    Nov

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Conference/Events
Morgan Stanley healthcare analysts to hold a luncheon »

Healthcare Analysts host…

SPLK

Splunk

$99.00

1.15 (1.18%)

, SAP

SAP

$104.09

0.23 (0.22%)

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Conference/Events
Wedbush enterprise software analyst to hold a luncheon »

Enterprise Software…

SPLK

Splunk

$99.00

1.15 (1.18%)

SAP

SAP

$104.09

0.23 (0.22%)

ORCL

Oracle

$49.62

0.78 (1.60%)

PANW

Palo Alto Networks

$171.57

-5.26 (-2.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 29

    Nov

  • 29

    Nov

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 09

    Jan

  • 10

    Jan

LOXO

Loxo Oncology

$147.40

3.71 (2.58%)

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Conference/Events
Loxo Oncology management to meet with Morgan Stanley »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

11:25
11/15/18
11/15
11:25
11/15/18
11:25
Conference/Events
RBC Capital software analysts to hold a group luncheon »

Software Analysts Hedberg…

MO

Altria Group

$58.61

-0.48 (-0.81%)

, BTI

British American Tobacco

$35.55

-0.96 (-2.63%)

11:22
11/15/18
11/15
11:22
11/15/18
11:22
Hot Stocks
CVS 'applauds' FDA announcement to restrict flavored tobacco products »

CVS Health (CVS)…

MO

Altria Group

$58.61

-0.48 (-0.81%)

BTI

British American Tobacco

$35.55

-0.96 (-2.63%)

PM

Philip Morris

$85.26

-0.25 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
11/15/18
11/15
11:20
11/15/18
11:20
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/15/18
11/15
11:17
11/15/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.